

bluebird bio, Inc.  
Form 8-K  
December 06, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 3, 2016

bluebird bio, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE

001-35966

13-3680878

(State or other jurisdiction of  
incorporation)

(Commission File Number)

(I.R.S. Employer  
Identification No.)

150 Second Street

Cambridge, MA

02141

Edgar Filing: bluebird bio, Inc. - Form 8-K

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (339) 499-9300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 8.01 Other Events

On December 3, 2016, bluebird bio, Inc. (“bluebird”) issued a press release announcing clinical data from its HGB-205 study of the LentiGlobin product candidate, presented at the 58<sup>th</sup> Annual Meeting of the American Society of Hematology (“ASH”) on December 3, 2016. The full text of the press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On December 5, 2016, bluebird issued a press release announcing clinical data from its Northstar (HGB-204) and HGB-206 studies of its LentiGlobin product candidate presented at ASH on December 5, 2016, and of clinical development plans for its Lenti-D product candidate. The full text of the press release regarding this announcement is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release
99.2	issued by bluebird bio, Inc. on December 3, 2016
	Press release issued by bluebird bio, Inc. on December 5, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 5, 2016 bluebird bio,  
Inc.

By: /s/  
Jason  
F. Cole  
Jason  
F. Cole  
Chief  
Legal  
Officer

---

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release
99.2	issued by bluebird bio, Inc. on December 3, 2016
	Press release issued by bluebird bio, Inc. on December 5, 2016